Meta‐Analysis: Evaluating Placebo Rates Across Outcomes in Eosinophilic Oesophagitis Randomised Controlled Trials
Alimentary Pharmacology & Therapeutics · 2025
DOI: 10.1111/apt.18382 ↗At a glance
Metaanalyse in Alimentary Pharmacology & Therapeutics, 2025. Written by Angelica Rivas and 9 co-authors. Institution: Department of Medicine, University of Calgary, Calgary, Alberta, Canada. Major MEDLINE topics: Eosinophilic Esophagitis, Randomized Controlled Trials as Topic. Cited 7 times so far (Crossref); 56 references. The full text is freely available (open access, CC BY-NC 4.0).
Abstract (original language)
Background
High placebo responses have limited drug development in eosinophilic oesophagitis. The optimal configuration of trial outcomes is uncertain.
Aims
To inform more efficient future trial designs, to characterise clinical, endoscopic and histologic placebo responses in eosinophilic oesophagitis randomised controlled trials (RCTs).
Methods
We updated a Cochrane systematic review and meta‐analysis, searching multiple databases to January 1, 2024, to identify placebo‐controlled RCTs evaluating medical therapies for patients with eosinophilic oesophagitis. The primary outcome was the pooled proportion of study‐defined clinical, endoscopic and histologic responders and remitters randomised to placebo, using an intention‐to‐treat approach and random‐effects model. Sources of heterogeneity were explored using meta‐regression.
Results
We included 25 RCTs. The pooled proportion of clinical response was 41.0% [95% CI: 29.7%–52.8%] with substantial heterogeneity ( I 2 = 74.9%). On meta‐regression, older age and a higher probability of being randomised to placebo reduced the likelihood of clinical response to placebo. The pooled proportion of histologic remission defined as a peak eosinophil count [PEC] ≤ 6 eosinophils per high power field [HPF] or ≤ 1 eosinophil/HPF was 4.3% [95% CI: 2.6%–6.2%] ( I 2 = 23.6%) and 1.3% [95% CI: 0.5%–2.5%] ( I 2 = 0%), respectively. The standardised mean difference in the Eosinophilic Oesophagitis Endoscopic Reference Score to placebo was −0.25 [95% CI: −0.41, −0.10].
Conclusions
Over 40% of patients in eosinophilic oesophagitis trials respond clinically to placebo, and this is associated with trial design factors such as randomisation ratio and trial population. Objective endoscopic and histologic measures are associated with very low placebo responses.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Department of Medicine, University of Calgary, Calgary, Alberta, Canada.
- Division of Gastroenterology, London Health Science Centre, London, Ontario, Canada.
- Department of Medicine, Western University, London, Ontario, Canada.
- Alimentiv Inc, London, Ontario, Canada.
- Department of Epidemiology and Biostatistics, Western University, London, Ontario, Canada.
- Department of Gastroenterology and Hepatology, Amsterdam University Medical Center, Amsterdam, The Netherlands.
ORCID profiles: Vipul Jairath, Christopher Ma
Cite
APA
Rivas, A., Ahmed, N. S., Yuan, Y., Qasim, A., O'Gorman, D. B., Feagan, B. G., Jairath, V., Bredenoord, A. J., Dellon, E. S., & Ma, C. (2025). Meta‐Analysis: Evaluating Placebo Rates Across Outcomes in Eosinophilic Oesophagitis Randomised Controlled Trials. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.18382
Vancouver
Rivas A, Ahmed NS, Yuan Y, Qasim A, O'Gorman DB, Feagan BG, et al. Meta‐Analysis: Evaluating Placebo Rates Across Outcomes in Eosinophilic Oesophagitis Randomised Controlled Trials. Alimentary Pharmacology & Therapeutics. 2025. doi:10.1111/apt.18382
BibTeX
@article{Rivas2025,
author = {Rivas, Angelica and Ahmed, Newaz Shubidito and Yuan, Yuhong and Qasim, Anila and O'Gorman, David B and Feagan, Brian G and Jairath, Vipul and Bredenoord, Albert J and Dellon, Evan S and Ma, Christopher},
title = {Meta‐Analysis: Evaluating Placebo Rates Across Outcomes in Eosinophilic Oesophagitis Randomised Controlled Trials},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2025},
doi = {10.1111/apt.18382}
}
EUVIMED